Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-124624
Filing Date
2024-11-12
Accepted
2024-11-12 08:05:21
Documents
53
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rapt-20240930.htm   iXBRL 10-Q 1788776
2 EX-31.1 rapt-ex31_1.htm EX-31.1 16613
3 EX-31.2 rapt-ex31_2.htm EX-31.2 16638
4 EX-32.1 rapt-ex32_1.htm EX-32.1 17024
  Complete submission text file 0000950170-24-124624.txt   5843500

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rapt-20240930.xsd EX-101.SCH 671775
55 EXTRACTED XBRL INSTANCE DOCUMENT rapt-20240930_htm.xml XML 907957
Mailing Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 489-9000
RAPT Therapeutics, Inc. (Filer) CIK: 0001673772 (see all company filings)

EIN.: 473313701 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38997 | Film No.: 241443544
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)